No Data
Longshen Rongfa: Report for the third quarter of 2024
Express News | gansu longshenrongfa pharmaceutical industry: net income in the first three quarters was 24.7672 million yuan, a year-on-year decrease of 47.11%.
gansu longshenrongfa pharmaceutical industry (300534.SZ): net income in the third quarter was 3.3142 million yuan, a decrease of 77.35% year-on-year.
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) announced its third quarter report for 2024 on October 22. During the reporting period, the revenue was 0.255 billion yuan, an increase of 15.64% year-on-year; the net income attributable to shareholders of the listed company was 3.3142 million yuan, a decrease of 77.35% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.8144 million yuan, a decrease of 79.13% year-on-year; the basic earnings per share was 0.0109 yuan.
gansu longshenrongfa pharmaceutical industry (300534.SZ): a holding subsidiary has obtained the "Pharmaceutical Production License" after exchange issuance.
On October 15, Gelonhui announced that its holding subsidiary Puan Pharmaceutical, based on daily operational management needs, applied to change the legal representative and enterprise leader in the Drug Production License from Kang Yonghong to Wang Minghong. The change procedures were legally completed and recently received the Drug Production License reissued by Gansu Provincial Drug Administration.
Longshenrongfa Pharma Gets Certification for Energy, Quality Management, Safety, Environment
Gansu Longshenrongfa Pharmaceutical Gets Re-Registration Approval for 13 Drugs
No Data
No Data